Tyzeka is a new oral antiviral for chronic hepatitis B

  Tyzeka is a new oral antiviral for chronic hepatitis B.

  It's an alternative to using lamivudine (Epivir-HBV)...adefovir (Hepsera)...entecavir (Baraclude)...or interferons (Pegasys, etc).

  Tyzeka (telbivudine) is well-tolerated like lamivudine...but it's more effective at suppressing the hepatitis B virus.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote